Story

On air. The free wire runs 15 minutes behind live. See pricing

World, crypto, finance and tech news, scored for impact.

MarketsSEC EDGAR SCHEDULE 13GFiled 3 days ago

C4 Therapeutics, Inc.: Squadron Capital Management LLC amends Schedule 13G stake filing

Open the sourceReported by SEC EDGAR SCHEDULE 13G, sec.gov, 16 November 2026, by SEC EDGAR SCHEDULE 13G

Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.

Squadron Capital Management LLC amended its Schedule 13G filing on C4 Therapeutics, Inc., updating its passive stake disclosure with the SEC under accession number 0002050709-26-000030. The filing signals a change in the institutional investor's reported position in the clinical-stage biotech, though the amended document did not specify the revised share count or percentage in the headline disclosure. C4 Therapeutics develops targeted protein degradation therapies, a sector where institutional ownership shifts can draw scrutiny given the company's reliance on pipeline milestones. Investors will watch for the full amended filing details to gauge whether Squadron's position increased or was trimmed, and for any subsequent 13F or Form 4 disclosures that clarify the direction of the stake.

Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.

Named in this story

Squadron Capital Management LLC, C4 Therapeutics, Inc.